Novo Plans Phase III Program To Pick Up Obesity Claim For Victoza
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novo Nordisk is moving ahead with plans to develop Victoza (liraglutide) for obesity now that U.S. regulators are comfortable with the GLP-1's risk/benefit profile
You may also be interested in...
Novo Nordisk's GLP-1 Victoza Off To A Good Start
New head-to-head study against popular oral Januvia could bolster case for use as a second-line agent in diabetes, company says.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product